Edition:
United Kingdom

Akers Biosciences Inc (AKER.OQ)

AKER.OQ on NASDAQ Stock Exchange Capital Market

0.59USD
18 May 2018
Change (% chg)

$0.08 (+16.25%)
Prev Close
$0.51
Open
$0.53
Day's High
$0.70
Day's Low
$0.52
Volume
3,531,708
Avg. Vol
2,622,241
52-wk High
$1.82
52-wk Low
$0.12

Chart for

About

Akers Biosciences, Inc. develops, manufactures and supplies point-of-care screening and testing products designed to bring health-related information to the patient or clinician. The Company's product offerings and pipeline products focus on delivering diagnostic assistance in a range of healthcare fields/specialties, including... (more)

Overall

Beta: -0.12
Market Cap(Mil.): $7.70
Shares Outstanding(Mil.): 8.90
Dividend: --
Yield (%): --

Financials

  AKER.OQ Industry Sector
P/E (TTM): -- 84.06 32.75
EPS (TTM): -0.41 -- --
ROI: -60.68 1.57 14.38
ROE: -60.68 2.43 16.07

BRIEF-Akers Biosciences Files Non Timely 10-Q - SEC Filing

* AKERS BIOSCIENCES INC FILES NON TIMELY 10-Q - SEC FILING Source text: (https://bit.ly/2k6a2jr) Further company coverage:

16 May 2018

BRIEF-Akers Biosciences Says Terminated Raymond Akers Positions As Executive Chairman

* SAYS TERMINATED RAYMOND AKERS POSITIONS AS EXECUTIVE CHAIRMAN, CHIEF SCIENTIFIC DIRECTOR AND SECRETARY OF COMPANY

26 Apr 2018

BRIEF-Akers Biosciences Says Appointed Richard Carlyle Tarbox III As Interim Non-Executive Chairman

* AKERS BIOSCIENCES - BOARD TERMINATED RAYMOND AKERS FROM POSITION AS EXECUTIVE CHAIRMAN OF BOARD, CHIEF SCIENTIFIC DIRECTOR AND SECRETARY OF COMPANY

25 Apr 2018

BRIEF-Akers Biosciences Expands Outsourced U.S. Distribution Capabilities For Heparin PF4 Rapid Test

* AKERS BIOSCIENCES EXPANDS OUTSOURCED US DISTRIBUTION CAPABILITIES FOR HEPARIN PF4 RAPID TEST

12 Apr 2018

BRIEF-Akers Biosciences Reports Earnings For Fiscal Year 2017

* AKERS BIOSCIENCES REPORTS EARNINGS FOR FISCAL YEAR 2017 Source text for Eikon: Further company coverage:

03 Apr 2018

BRIEF-Akers Biosciences Signs Distribution Agreement With Diagnostica Stago

* AKERS BIOSCIENCES SIGNS US DISTRIBUTION AGREEMENT WITH DIAGNOSTICA STAGO

26 Mar 2018

BRIEF-Akers Biosciences Announces Distribution Agreement With Diagnostica Stago​

* ‍ENTERED INTO 3-YEAR DISTRIBUTION AGREEMENT WITH DIAGNOSTICA STAGO FOR SALE OF CO'S RAPID TEST FOR HEPARIN-INDUCED THROMBOCYTOPENIA ACROSS US​ Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

26 Mar 2018

BRIEF-Alpha Capital Anstalt Reports 9.9 Pct Passive Stake In Akers Biosciences

* ALPHA CAPITAL ANSTALT REPORTS 9.9 PERCENT PASSIVE STAKE IN AKERS BIOSCIENCES INC AS ON DECEMBER 21 - SEC FILING Source text (http://bit.ly/2BZ9Q04) Further company coverage:

22 Dec 2017

Earnings vs. Estimates